Poniard Pharmaceuticals (PARD) Stock Statistics & Valuation Metrics

Poniard Pharmaceuticals has a market cap or net worth of $150.00. The enterprise value is ―.

Poniard Pharmaceuticals has 1,499,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Poniard Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Poniard Pharmaceuticals is ―. Poniard Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Poniard Pharmaceuticals had revenue of ― and earned -30.05M in profits. Earnings per share was ―.

In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.

Poniard Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Poniard Pharmaceuticals upcoming earnings date is ―, ―.

Poniard Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Poniard Pharmaceuticals has paid ― in taxes.

Poniard Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Poniard Pharmaceuticals has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Poniard Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―